Disease-modifying effect of Zonisamide with the induction of BDNF and TrkB expression
Objective: To evaluate to predictors of the disease-modifying effect of drugs on Parkinson’s disease (DM-PD) according to long-term therapeutic investigation, especially regarding the non-dopaminergic agent…Development of a prototype alpha-synuclein vaccine to induce T regulatory cells for the treatment of synucleonopathy
Objective: Test the hypothesis that combining humoral and immunosuppressive cellular asyn immunization will enhance asyn clearance, and reduce inflammation and neuropathological symptoms in a human…Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease
Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease
Objective: To develop small molecular weight compounds (SMEs) as disease-modifying agents, which are designed to arrest or even reverse the aggregation process of alpha-synuclein (aSyn)…Randomized Parkinson’s Trial of GDNF Administered via Intermittent Intraputamenal Convection-Enhanced Delivery.
Objective: Assesing the neurorestorative effect of GDNF. Background: GDNF is a potent neurotrophic factor. A previous placebo-controlled trial, however, at 6 months, failed to demonstrate…Communication Calendar for Interdisciplinary Therapy of Parkinson’s Disease
Objective: To develop a communication calendar (CC) to facilitate information exchange about outpatients treated by various therapists in order to optimize interdisciplinary therapy of Parkinson's…Physical activity habits in early Parkinson’s disease and healthy controls
Objective: Investigate the physical activity habits of Parkinson’s disease (PD) and healthy control (HC) participants of the PPMI cohort. Background: Exercise can improve the motor…Identification of a trehalose treatment regimen with potential to be translated into a therapeutic for the treatment of Parkinson’s disease
Objective: To evaluate the preclinical efficacy of trehalose and to identify a dosing regimen that can be used to clinically evaluate trehalose as a disease-modifying therapy…Clinical and Imaging and phenoconversion in the PARS prodromal cohort
Objective: We report clinical and imaging phenoconversion data at 6 years follow-up for the PARS cohort. Background: The PARS cohort consists of 203 hyposmic and…Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes
Objective: In this study, we examined neuroprotective effects of mirtazapine and involvement of astrocytes in the effects using primary cultured cells and parkinsonian mice. Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.